Recruitment opens for Phase II trial in prostate cancer with Cu-64 SAR-Bombesin in the US
Sydney, Australia 5 September 2022 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the US-based diagnostic 64Cu SAR-Bombesin trial (SABRE NCT05407311)1 for patients with PSMA-negative prostate cancer is open for recruitment. SABRE (Copper-64…